Pseudoexfoliation Syndrome in Northwest Ethiopia Cataract Patients

Why It Matters

The findings highlight a hidden burden of PXF in a vulnerable population, prompting urgent integration of PXF screening into cataract care to prevent vision‑loss complications and guide public‑health interventions.

Key Takeaways

• PXF prevalence high among Ethiopian cataract patients.
• UV exposure and genetics linked to syndrome.
• Hypertension, diabetes show limited association.
• Early detection reduces surgical complications.
• Data supports tailored screening in low-resource settings.

Pulse Analysis

Pseudoexfoliation syndrome, an age‑related systemic disorder, is a leading cause of secondary glaucoma and complicates cataract surgery worldwide. While prevalence rates vary—from the Nordic countries to East Asia—data from sub‑Saharan Africa have been scarce. This Ethiopian study fills a critical knowledge gap by providing robust epidemiological evidence that PXF is common among cataract patients in the region, underscoring the need for clinicians to incorporate routine PXF checks during pre‑operative assessments.

The investigation revealed that environmental factors such as intense ultraviolet radiation and oxidative stress, combined with genetic susceptibility, drive the high PXF rates observed. Although hypertension and diabetes are frequently cited as comorbidities, multivariate analysis indicated they contribute minimally to PXF onset in this cohort. Importantly, the presence of pseudoexfoliative material heightened the risk of intra‑operative challenges, including zonular weakness and capsular rupture, reinforcing the value of early identification to adapt surgical techniques and improve outcomes.

Beyond clinical practice, the study’s implications extend to health policy and research agendas. Tailored screening protocols in low‑resource ophthalmic centers can reduce preventable blindness by catching PXF before cataract extraction. Moreover, the authors advocate for genetic and proteomic studies within Ethiopian populations to uncover unique biomarkers, potentially leading to targeted therapies. As global aging accelerates cataract incidence, integrating PXF surveillance into eye‑care programs will be essential for equitable vision health worldwide.